{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:24:00Z","timestamp":1740144240428,"version":"3.37.3"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"22","license":[{"start":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T00:00:00Z","timestamp":1590710400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Science and Technology Program of Sichuan Province in 2019: Research on comprehensive TCM prevention and treatment of diabetic foot diseases based on the combination of \u201cdisease-syndrome-symptom\u201d","award":["2019YFS0085"],"award-info":[{"award-number":["2019YFS0085"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction:<\/jats:title>\n            <jats:p>The prevalence of diabetes continues to rise around the world. Diabetic foot is a serious complication of diabetes, and diabetic patients with diabetic foot osteomyelitis (DFO) have a fourfold increased risk of amputation, usually indicating death. Therefore, it is particularly important to seek a more effective treatment for DFO. The treatment of DFO varies from person to person, and antimicrobial therapies vary widely. A large number of clinical studies have shown that rifampicin adjuvant therapy can reduce the rate of amputation and mortality in DFO patients. However, there is no systematic summary of clinical evidence, which limits the clinical application of rifampicin. Therefore, we attempted to provide high-quality evidence for the clinical efficacy and safety of rifampin in the adjuvant treatment of DFO through this meta-analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>English literature is mainly searched in Cochrane Library, PubMed, EMBASE and Web of Science, while Chinese literature is from CNKI, CBM, VIP and Wangfang databases. At the same time, we will search clinical registration tests and gray literature. Two methodologically trained researchers will read the title, abstract, and full text, and independently select qualified literature based on inclusion and exclusion criteria. Binary data is expressed as relative risk, continuous data is expressed as mean difference or standard mean difference. The final data are synthesized using a fixed effect model or a random effect model, depending on the presence of heterogeneity. In the end, the patient's amputation rate and mortality were the main research indicators. Survival rate, HbA1c, serum creatinine, changes in ulcer area, and SF-36 quality of life assessment were used as secondary indicators. We will perform a sensitivity analysis to assess the stability of the results. Then the publication bias was evaluated by funnel plot analysis and Egger test. Finally, we will use a \u201crecommendation grading, evaluation, formulation and evaluation\u201d system to assess the quality of the evidence. All data analysis will be meta-analyzed by the statistical software RevMan software version 5.3.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>This study will provide a high-quality comprehensive report on the effectiveness and safety of rifampicin in the treatment of DFO, and our findings will be published in peer-reviewed journals.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>This systematic review and meta-analysis will provide a comprehensive summary and careful evaluation of rifampicin as an adjuvant treatment of DFO with a view to providing multiple options for clinical treatment of the disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Registration number:<\/jats:title>\n            <jats:p>is INPLASY202040084.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000020375","type":"journal-article","created":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T19:25:06Z","timestamp":1590693906000},"page":"e20375","source":"Crossref","is-referenced-by-count":1,"title":["Adjunctive rifampin therapy for diabetic foot osteomyelitis"],"prefix":"10.1097","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4604-751X","authenticated-orcid":false,"given":"Yanli","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengju","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shasha","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiping","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,5,29]]},"reference":[{"key":"R1-20240308","doi-asserted-by":"crossref","first-page":"714","DOI":"10.3390\/medicina55110714","article-title":"Current therapeutic strategies in diabetic foot ulcers","volume":"55","author":"Perez-Favila","year":"2019","journal-title":"Medicina"},{"journal-title":"Brussels, Belgium","article-title":"IDF diabetes atlas international diabetes federation","year":"2015","key":"R2-20240308"},{"key":"R3-20240308","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.diabres.2018.02.023","article-title":"IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045","volume":"138","author":"Cho","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"R4-20240308","first-page":"885","article-title":"National guidelines for the prevention and control of diabetes in primary care (2018)","volume":"57","author":"Chinese","year":"2018","journal-title":"Zhonghua nei ke za zhi"},{"key":"R5-20240308","doi-asserted-by":"crossref","first-page":"62","DOI":"10.5312\/wjo.v6.i1.62","article-title":"Diabetic foot syndrome: Immune-inflammatory features as possible cardiovascular markers in diabetes","volume":"6","author":"Tuttolomondo","year":"2015","journal-title":"World J Orthop"},{"key":"R6-20240308","first-page":"897","article-title":"Wound bed preparation for ischemic diabetic foot ulcer","volume":"8","author":"Zhang","year":"2015","journal-title":"International journal of clinical and experimental medicine"},{"key":"R7-20240308","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1093\/cid\/cis346","article-title":"2012 Infectious diseases society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections","volume":"54","author":"Lipsky","year":"2012","journal-title":"Clin Infect Dis"},{"key":"R8-20240308","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(14)61233-2","article-title":"Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial","volume":"385","author":"Bernard","year":"2015","journal-title":"Lancet"},{"key":"R9-20240308","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/jac\/48.6.927","article-title":"Rifampicin\u2013ofloxacin oral regimen for the treatment of mild to moderate diabetic foot osteomyelitis","volume":"48","author":"Senneville","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"R10-20240308","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2337\/dc07-1744","article-title":"Outcome of diabetic foot osteomyelitis treated nonsurgically: a retrospective cohort study","volume":"31","author":"Senneville","year":"2008","journal-title":"Diabetes Care"},{"key":"R11-20240308","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1056\/NEJMoa1710926","article-title":"Oral versus intravenous antibiotics for bone and joint infection","volume":"380","author":"Li","year":"2019","journal-title":"N Engl J Med"},{"key":"R12-20240308","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1128\/AAC.04359-14","article-title":"Antimicrobial activity against intraosteoblastic Staphylococcus aureus","volume":"59","author":"Valour","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"R13-20240308","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1128\/AAC.50.1.55-61.2006","article-title":"Multiple combination bactericidal testing of staphylococcal biofilms from implant-associated infections","volume":"50","author":"Saginur","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R14-20240308","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nature12790","article-title":"Activated ClpP kills persisters and eradicates a chronic biofilm infection","volume":"503","author":"Conlon","year":"2013","journal-title":"Nature"},{"key":"R15-20240308","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1097\/00007611-198608000-00008","article-title":"Chronic osteomyelitis caused by Staphylococcus aureus: controlled clinical trial of nafcillin therapy and nafcillin-rifampin therapy","volume":"79","author":"Norden","year":"1986","journal-title":"South Med J"},{"key":"R16-20240308","first-page":"10","article-title":"Cotrimoxazole plus rifampicin in the treatment of staphylococcal osteoarticular infection","volume":"15","author":"Sanchez","year":"1997","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"R17-20240308","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/cid\/cir842","article-title":"Systemic antibiotic therapy for chronic osteomyelitis in adults","volume":"54","author":"Spellberg","year":"2012","journal-title":"Clin Infect Dis"},{"key":"R18-20240308","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3109\/00365548.2013.865141","article-title":"In vitro activity of rifampicin alone and in combination with imipenem against multidrug-resistant Acinetobacter baumannii harboring the bla OXA-72 resistance gene","volume":"46","author":"Majewski","year":"2014","journal-title":"Scandinavian journal of infectious diseases"},{"issue":"(Supplement_3)","key":"R19-20240308","doi-asserted-by":"crossref","first-page":"S502","DOI":"10.1093\/clinids\/5.Supplement_3.S502","article-title":"Use of rifampin for the treatment of serious staphylococcal and gram-negative bacillary infections","volume":"5","author":"Acar","year":"1983","journal-title":"Rev Infect Dis"},{"key":"R20-20240308","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1128\/AAC.28.4.467","article-title":"Double-blind, placebo-controlled study of oxacillin combined with rifampin in the treatment of staphylococcal infections","volume":"28","author":"Van Der Auwera","year":"1985","journal-title":"Antimicrob Agents Chemother"},{"key":"R21-20240308","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1001\/jama.279.19.1537","article-title":"Role of rifampin for treatment of orthopedic implant\u2013related staphylococcal infections: a randomized controlled trial","volume":"279","author":"Zimmerli","year":"1998","journal-title":"JAMA"},{"key":"R22-20240308","first-page":"e1916003","article-title":"Adjunctive rifampin therapy for diabetic foot osteomyelitis in the veterans health administration","volume":"2","author":"Wilson","year":"2019","journal-title":"JAMA"},{"key":"R23-20240308","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-019-4751-3","article-title":"A multicenter randomized placebo controlled trial of rifampin to reduce pedal amputations for osteomyelitis in veterans with diabetes (VA INTREPID)","volume":"20","author":"Bessesen","year":"2020","journal-title":"BMC Infect Dis"},{"key":"R24-20240308","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"issue":"(S1)","key":"R25-20240308","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.1002\/dmrr.836","article-title":"Diabetic foot osteomyelitis: a progress report on diagnosis and a systematic review of treatment","volume":"24","author":"Berendt","year":"2008","journal-title":"Diabetes Metab Res Rev"},{"issue":"(Suppl 1)","key":"R26-20240308","first-page":"S34","article-title":"American diabetes association standards of medical care in diabetes\u20132019","volume":"42","author":"Riddle","year":"2019","journal-title":"Diabetes Care"},{"key":"R28-20240308","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J Clin Epidemiol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020375","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T20:22:33Z","timestamp":1709929353000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020375"}},"subtitle":["A protocol for systematic review and meta-analysis"],"short-title":[],"issued":{"date-parts":[[2020,5,29]]},"references-count":27,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000020375","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2020,5,29]]}}}